December 6: The Week in Cancer News
HPV vaccine credited for decrease in cervical cancer deaths among young women, and new technology extends survival in locally advanced pancreatic cancer.
Progress Against Cancer
HPV vaccine credited for decrease in cervical cancer deaths among young women, and new technology extends survival in locally advanced pancreatic cancer.
Pancreatic cancer surge in younger people has not led to a rise in deaths, and researchers will study long-term survivors to better understand cancer responses.
The FDA granted accelerated approval to the first-in-class HER2-directed bispecific antibody zanidatamab-hrii. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanidatamab-hrii (Ziihera) for previously treated, unresectable or metastatic human epidermal...
The FDA Project Renewal initiative has updated the approved indications for fludarabine phosphate chemotherapy in chronic lymphocytic leukemia. The U.S. Food and Drug Administration (FDA) has approved updated labeling of fludarabine phosphate (Fludarabine Phosphate...
Using high-dose testosterone after prostate cancer stops responding to androgen deprivation therapy can stop tumor growth.
The FDA approved revumenib, a first-in-class menin inhibitor, to treat acute leukemias with a KMT2A translocation. The U.S. Food and Drug Administration (FDA) has approved revumenib (Revuforj) for the treatment of adult and pediatric...
Complications can affect men years after prostate cancer treatment, and many people eligible for lung cancer screening do not get it.
Combination of radiation, chemotherapy, and immunotherapy can shrink tumors and allow surgery, with much better survival rate rather than with non-surgical treatment alone. In some cases of advanced esophageal cancer that are considered to...
Early initiation of palliative care leads to fewer hospital admissions, and surgery that removes fewer lymph nodes is effective for localized muscle-invasive bladder cancer.
The cell-based immunotherapy was approved for adults with relapsed or refractory acute lymphoblastic leukemia. The U.S. Food and Drug Administration (FDA) has approved obecabtagene autoleucel (Aucatzyl) for the treatment of adults with relapsed or...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now